Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619931 · ClinicalTrials.gov registry record · Phase 1
A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
A Phase 1 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00619931 is a Phase 1 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT00619931, a Phase 1 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.
Interventions
- DRUG APD791
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619931
The ClinicalTrials.gov registry entry for NCT00619931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APD791 is the first listed.
NCT00619931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619931 about?
NCT00619931 is a clinical study titled "A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers". The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.
What is the current status of trial NCT00619931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2008-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00619931?
The interventions under investigation include: APD791 (DRUG).
Who is sponsoring clinical trial NCT00619931?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.